Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a dissolvable glue seal the brain and stop leaks after surgery?

NCT ID NCT07768553

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This clinical trial is testing whether a new absorbable adhesive can help seal the protective lining of the brain (the dura) after neurosurgery, preventing cerebrospinal fluid leaks. The study involves 132 adults who are having brain or spinal surgery and are at risk of such leaks. Participants are randomly assigned to receive either the new adhesive or an existing sealing film, and the success of the seal is checked about a week after surgery. The goal is to see if the new adhesive works as well as the current option, with fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
An absorbable medical adhesive made of polyethylene glycol (PEG) derivatives that forms a hydrogel to seal the dura during neurosurgery.
What this could lead to
If effective, this adhesive could offer a new way to prevent cerebrospinal fluid leaks after brain or spinal surgery, potentially reducing complications and the need for additional procedures.
What could go wrong
This is a Phase 3 trial with a relatively small number of participants (132). The adhesive may not be as effective as the existing sealing film, and there are risks of infection, swelling, or other surgical complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

132 people

The number who actually took part.

Started

Nov 2017

Finished

Sep 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years and ≤ 75 years, any gender. * Patients undergoing neurosurgical dural (or spinal dural) repair who are at risk of CSF leakage or who have already developed CSF leakage and require adjunctive repair. * Patient and/or legal guardian has provided written informed consent. Exclusion Criteria: * Participated in another clinical trial within 1 month prior to screening. * Body temperature ≥ 37.3°C within 3 days prior to screening. * Severe diseases of vital organs (heart, liver, kidney) or hematological diseases that would make the patient intolerant to surgery. * History of severe allergies or severe immunodeficiency. * Life expectancy \< 3 months. * Pregnant or breastfeeding women, or women of childbearing age with positive pregnancy test; male or female subjects not using effective contraception or planning to conceive within 3 months after study initiation. * Poor compliance as judged by the investigator. * Unable to understand the study description. * Any other condition deemed unsuitable for participation as judged by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrospinal fluid leak are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Huazhong University of Science and Technology Union Shenzhen Hospital (Shenzhen Nanshan People's Hospital)

    Shenzhen, Guangdong, China

  • Qinghai Provincial People's Hospital

    Xining, Qinghai, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

  • Tangdu Hospital, Air Force Medical University

    Xi'an, Shaanxi, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.